MY128296A - Crystalline pharmaceutical - Google Patents

Crystalline pharmaceutical

Info

Publication number
MY128296A
MY128296A MYPI20011034A MYPI20011034A MY128296A MY 128296 A MY128296 A MY 128296A MY PI20011034 A MYPI20011034 A MY PI20011034A MY PI20011034 A MYPI20011034 A MY PI20011034A MY 128296 A MY128296 A MY 128296A
Authority
MY
Malaysia
Prior art keywords
peak
amino
range
crystalline pharmaceutical
solid state
Prior art date
Application number
MYPI20011034A
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY128296(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MY128296A publication Critical patent/MY128296A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

THERE IS DISCLOSED A NON-SOLVATED CRYSTALLINE FORM OF THE COMPOUND (2S,3S,5S)-2-(2,6 DIMETHYLPHENOXYACETYL)AMINO-3-HYDROXY-5-(2-(1-TETRAHYDRO PYRIMID-2-ONYL)-3-METHYLBUTANOYL)) AMINO-1,6-DIPHENYLHEXANE WITH A PEAK IN THE SOLID STATE INFRARED SPECTRUM AT A POSITION WITHIN THE RANGE 1680-1685 CM¯¹ AND A PEAK IN THE SOLID STATE INFRARED SPECTRUM AT A POSITION WITHIN THE RANGE 1625-1630 CM¯¹.(FIG 1)
MYPI20011034A 2000-03-30 2001-03-07 Crystalline pharmaceutical MY128296A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
MY128296A true MY128296A (en) 2007-01-31

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20011034A MY128296A (en) 2000-03-30 2001-03-07 Crystalline pharmaceutical

Country Status (22)

Country Link
EP (1) EP1268442A2 (en)
JP (1) JP2003529592A (en)
KR (1) KR100773258B1 (en)
CN (2) CN101066952A (en)
AR (2) AR033360A1 (en)
AU (3) AU5092001A (en)
BG (1) BG107165A (en)
BR (1) BR0109433A (en)
CA (1) CA2403635A1 (en)
CZ (1) CZ20023529A3 (en)
HU (1) HUP0302675A3 (en)
IL (1) IL151551A0 (en)
MX (1) MXPA02009559A (en)
MY (1) MY128296A (en)
NO (1) NO325005B1 (en)
NZ (1) NZ521183A (en)
PE (1) PE20011232A1 (en)
PL (1) PL359727A1 (en)
SA (2) SA01220270B1 (en)
SK (1) SK14832002A3 (en)
TW (1) TWI284640B (en)
WO (1) WO2001074787A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2393786B1 (en) 2009-02-06 2014-01-22 Hetero Research Foundation Novel polymorphs of lopinavir
AU2010286681A1 (en) * 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (en) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 Novel lopinavir crystal form and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
NZ521183A (en) 2004-03-26
KR20030011807A (en) 2003-02-11
HUP0302675A3 (en) 2004-03-29
CN1422259A (en) 2003-06-04
AU2001250920B2 (en) 2006-06-29
PE20011232A1 (en) 2001-12-08
WO2001074787A2 (en) 2001-10-11
CZ20023529A3 (en) 2003-02-12
IL151551A0 (en) 2003-04-10
KR100773258B1 (en) 2007-11-05
EP1268442A2 (en) 2003-01-02
CA2403635A1 (en) 2001-10-11
BR0109433A (en) 2004-08-10
CN101066952A (en) 2007-11-07
AU2006222711A1 (en) 2006-10-19
NO20024679D0 (en) 2002-09-30
SK14832002A3 (en) 2003-02-04
SA06270303B1 (en) 2009-08-02
AR049560A2 (en) 2006-08-16
SA01220270B1 (en) 2006-11-14
AR033360A1 (en) 2003-12-17
CN1330639C (en) 2007-08-08
JP2003529592A (en) 2003-10-07
HUP0302675A2 (en) 2003-12-29
TWI284640B (en) 2007-08-01
PL359727A1 (en) 2004-09-06
NO325005B1 (en) 2008-01-14
NO20024679L (en) 2002-09-30
AU5092001A (en) 2001-10-15
MXPA02009559A (en) 2003-05-21
WO2001074787A3 (en) 2002-02-07
BG107165A (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AUPQ325199A0 (en) An elongate member
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
AU2000264559A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
AU2002335536A1 (en) Pyrimidine compound and medicinal composition thereof
HUP0203165A3 (en) 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
AU2002252949A1 (en) 2-(Alpha-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE
AU2001233069A1 (en) Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
AU2001265933A1 (en) Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
AU4943800A (en) Management of non-mbeam objects in jmx environment
AU2002950853A0 (en) Aminopyrimidine compound and pharmaceutical use thereof
AU2001289606A1 (en) Dry powder formulation comprising racecadotril
MY128296A (en) Crystalline pharmaceutical
IL139899A0 (en) Uracil compounds and use thereof
CA2371554A1 (en) Pharmaceutical composition comprising an angiotensin ii antagonist for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy
AU2001262149A1 (en) 2-(indanylamino)pyrimidone and 2-(tetrahydronaphthalenylamino)pyrimidone derivatives
AU4503499A (en) Use of 2-(n-phenylamino)pyrimidines as fungicides, and novel 2-(n-phenylamino)pyrimidines
AU2003206694A1 (en) Substituted alkyl uracils and the use thereof
DE69912247D1 (en) E-2- (4- (CHLORO-1,2-DIPHENYLBUT-1-ENYL) PHENOXY) ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF
AU5569200A (en) Uracil compounds and use thereof
AU2267897A (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
USD424215S (en) Concrete wall forming extrusion
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
PL348601A1 (en) New pharmaceutical composition and the process for its preparation
USD423781S (en) Suitcase protection strip
AU2003264474A1 (en) Novel uracil derivatives and medicinal use thereof